Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study to Evaluate TAK-659 in Combination With Nivolumab in Patients With Advanced Solid Tumors

NCT02834247 is registered in ClinicalTrials.gov with Calithera Biosciences, Inc as lead sponsor.

NCT NCT02834247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02834247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study to Evaluate TAK-659 in Combination With Nivolumab in Patients With Advanced Solid Tumors
Lead sponsor
Calithera Biosciences, Inc
Phase
Phase 1
Overall status
Terminated
Start date
August 12, 2016
Completion date
November 30, 2018
Enrollment
41 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, carcinoma, non-small-cell lung, head and neck carcinoma, squamous cell, triple-negative breast neoplasms